<DOC>
	<DOCNO>NCT01511159</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial determine relative bioavailability NNC 90-1170 ( liraglutide ) inhale compare NNC 90-1170 injected skin .</brief_summary>
	<brief_title>Comparison Liraglutide Inhaled Into Lungs Compared Liraglutide Injected Under Skin Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>No clinically important abnormal physical finding No clinically relevant abnormality result laboratory screening evaluation Normal ( abnormal clinically significant ) ECG ( electrocardiogram ) Normal ( abnormal clinically significant ) blood pressure heart rate Body Mass Index ( BMI ) 2030 kg/m^2 outwith range clinically significant Nonsmoker Forced Vital Capacity ( FVC ) Forced Expiratory Volume 1 second ( FEV1 ) least 85 % predict normal age , gender height FVC ratio least 75 % predict normal age , gender height A clinically significant illness infection require treatment within last two month Any infection involve respiratory system adverse event may , opinion principal investigator , interfere blood glucose homeostasis Subjects first and/or second degree relative ( ) diabetes mellitus Donation loss great 500 ml blood period 012 week trial entry Alcohol use excess 28 unit alcohol per week . A unit alcohol equivalent half pint average strength beer , glass ( 125 ml ) wine pub measure ( 25 ml ) spirit , sherry port Current addiction alcohol substance abuse Females Presence hepatitis B surface antigen , hepatitis C antibody HIV ( human immunodeficiency virus ) 1 2 antibody</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>